Lupin is expecting 25-30 product approvals in FY 2016 and the number for financial year 2017 is likely to be even higher than this. With 10 final approvals in the past 12 months, the company has led the Indian pharma peers on this metric.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally.